Pneumonia, An Issue of Clinics in Chest Medicine

<p>Preface</p> <p>1. INFLAMMATION AND PNEUMONIA: WHY ARE SOME MORE SUSCEPTIBLE THAN OTHERS?</p> <p>2. THE LUNG MICROBIOME AND ITS ROLE IN PNEUMONIA</p> <p>3. BIOMARKERS FOR THE MANAGEMENT OF PNEUMONIA</p> <p>4. NFLUENZA AND VIRAL PNEUMONIA</p> <p>5. Guidelines to Manage Community-Acquired Pneumonia</p> <p>6. Vaccines to Prevent Community-Acquired Pneumonia</p> <p>7. Adjunctive Therapies for Community-Acquired Pneumonia</p> <p>8. HEALTHCARE ASSOCIATED PNEUMONIA: STILL A USEFUL CONCEPT?</p> <p>9. AIRWAY DEVICES IN VAP PATHOGENESIS AND PREVENTION</p> <p>10. MANAGEMENT OF VAP: GUIDELINES</p> <p>11. HOW CAN WE DISTINGUISH VENTILATOR ASSOCIATED TRACHEOBRONCHITIS FROM VAP?</p> <p>12. IS ZERO VAP ACHIEVABLE? PRACTICAL APPROACHES TO VAP PREVENTION</p> <p>13. AEROSOL THERAPY OF PNEUMONIA IN THE ICU </p> <p>14. Optimizing Antibiotic Administration for Pneumonia</p> <p>15. New Antibiotics for Pneumonia</p> <p>16. PERSONALIZED APPROACH TO PNEUMONIA MANAGEMENT</p>